Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a...
Staff
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing...
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases,...
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12...
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of...
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company...
Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment
Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, June 20, 2023 (GLOBE NEWSWIRE) --...
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW...
Aridis Pharmaceuticals’ AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
LPAD may provide alternative pathways for streamlined product approvalLOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....
Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting
Oak Ridge, TN, June 20, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023SAN DIEGO, June 20, 2023...
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
Quipt Home Medical Announces Up-listing to the Toronto Stock Exchange
CINCINNATI, June 20, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based...
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height...
invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501...
Cleantech Blue-Zone Technologies Signs Letter of Intent with Leading Medical Gas Equipment Manufacturer, Class 1
Parties consider collaborative agreement for the collection and conversion of anesthetic gasesTORONTO, June 19, 2023 (GLOBE NEWSWIRE) -- Blue-Zone Technologies...
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously...